Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Cornea and External Disease > What side effects of dry eye treatment are most important to patients?
  • Cornea and External Disease

What side effects of dry eye treatment are most important to patients?

Ophthalmology 360

Researchers utilized a Discrete Choice Experiment to determine which factors are important to patients with dry eye disease (DED) when choosing medications to potentially improve adherence.

Patients diagnosed with DED (n = 139) were given 10 choice tasks where they were asked to choose between their current medication (or no medication), and 2 hypothetical medications that varied based on 5 attributes, including duration of burning/stinging, duration of blurring, time to medication effectiveness, medication frequency, and out-of-pocket cost.

There were 2 groups with distinct preferences. The duration of burning/stinging and cost were the most important attributes for both groups whereas the duration of blurring was the least important.

There was an 18 percentage-point increase in predicted uptake of a medication when the duration of burning/stinging decreased to a few minutes from 2 hours.

“Predicted uptake for new medications was lowest for those on medication with well-controlled symptoms and highest for those who were not on medication and could not control their symptoms effectively,” the authors wrote.

Reference
Ozdemir S, Yeo SWJ, Lee JJ, et al. Patient Medication Preferences for Managing Dry Eye Disease: The Importance of Medication Side Effects. Patient. 2022;doi: 10.1007/s40271-022-00586-8. Epub ahead of print. PMID: 35697974.

Share

Related Content

  • Dry Eye

Analysis of FDA reports reveals widespread ocular adverse events linked to antidepressants

  • Cataract

Optimizing cataract surgery outcomes through dry eye management

  • Dry Eye

Preservative-free lubricants linked to improved dry eye symptoms in real-world study

  • Cornea and External Disease

Phase 3 trial of cenegermin-bkbj for PCED enrolls first US patient

  • Cornea and External Disease

Cornea specialists identify key clinical signs linked to microbial keratitis subtypes

Cornea Update: Corneal Dystrophies & Related Conditions with an Update on Genetic Assessment and Treatment
  • Cornea and External Disease

Preventing complications of superficial keratectomy

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon